Specialty and generic businesses will continue to do well for pharmaceutical companies, according to Sameer Baisiwala of Morgan Stanley.
The way indian pharma business models are going, specialty is going to be the fourth tier after APIs, domestics, exports and generics, Baisiwala told BloombergQuint in an interview on the sidelines of the Morgan Stanley conference. "There is enough and more opportunities in complex generics which you can expect," Baisiwala added.
Watch the interview here
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
